Cargando…
The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group
Prescription opioid misuse remains a significant cause of morbidity and mortality associated with drug overdose. Researchers, government agencies, public health interests, and professional organizations support the benefits of naloxone coprescribing for patients on chronic opioid therapy to prevent...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372947/ https://www.ncbi.nlm.nih.gov/pubmed/34949114 http://dx.doi.org/10.18553/jmcp.2022.28.1.100 |
_version_ | 1785078459636121600 |
---|---|
author | Skelton, Jann B Dharbhamalla, Vyishali |
author_facet | Skelton, Jann B Dharbhamalla, Vyishali |
author_sort | Skelton, Jann B |
collection | PubMed |
description | Prescription opioid misuse remains a significant cause of morbidity and mortality associated with drug overdose. Researchers, government agencies, public health interests, and professional organizations support the benefits of naloxone coprescribing for patients on chronic opioid therapy to prevent deaths from opioid overdose. However, gaps remain in the provision of naloxone to patients at risk. Currently, less than 1% of patients who should be prescribed naloxone with their opioid medications obtain a prescription for naloxone, illustrating an opportunity for health care providers to conduct thorough risk assessments for patients taking opioids and coprescribing naloxone to those at risk. There are documented barriers to the provision of naloxone for primary care providers, pharmacists, and patients. Managed care organizations have also created barriers. To better understand and evaluate trends in treatment, coverage, policies, and needs associated with providing health services to patients with substance use disorders, the Academy of Managed Care Pharmacy (AMCP) Addiction Advisory Group conducted a survey in 2019. Eighty percent of the managed behavioral health organizations and 47% of AMCP payer members who responded to the survey encouraged naloxone coprescribing in patients at high risk of overdose; however, no organizations require coprescribing. Health plans, managed care organizations, prescribers, pharmacists, patients, and others have important roles in decreasing the morbidity and mortality associated with opioid overdose. In particular, managed care organizations can take specific and meaningful actions to implement payment policies that improve naloxone coprescribing for patients at risk. In this article, opportunities have been outlined for managed care leadership that actively support public health policies for naloxone coprescribing, and 7 recommendations are presented. |
format | Online Article Text |
id | pubmed-10372947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-103729472023-07-31 The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group Skelton, Jann B Dharbhamalla, Vyishali J Manag Care Spec Pharm Viewpoints Prescription opioid misuse remains a significant cause of morbidity and mortality associated with drug overdose. Researchers, government agencies, public health interests, and professional organizations support the benefits of naloxone coprescribing for patients on chronic opioid therapy to prevent deaths from opioid overdose. However, gaps remain in the provision of naloxone to patients at risk. Currently, less than 1% of patients who should be prescribed naloxone with their opioid medications obtain a prescription for naloxone, illustrating an opportunity for health care providers to conduct thorough risk assessments for patients taking opioids and coprescribing naloxone to those at risk. There are documented barriers to the provision of naloxone for primary care providers, pharmacists, and patients. Managed care organizations have also created barriers. To better understand and evaluate trends in treatment, coverage, policies, and needs associated with providing health services to patients with substance use disorders, the Academy of Managed Care Pharmacy (AMCP) Addiction Advisory Group conducted a survey in 2019. Eighty percent of the managed behavioral health organizations and 47% of AMCP payer members who responded to the survey encouraged naloxone coprescribing in patients at high risk of overdose; however, no organizations require coprescribing. Health plans, managed care organizations, prescribers, pharmacists, patients, and others have important roles in decreasing the morbidity and mortality associated with opioid overdose. In particular, managed care organizations can take specific and meaningful actions to implement payment policies that improve naloxone coprescribing for patients at risk. In this article, opportunities have been outlined for managed care leadership that actively support public health policies for naloxone coprescribing, and 7 recommendations are presented. Academy of Managed Care Pharmacy 2022-01 /pmc/articles/PMC10372947/ /pubmed/34949114 http://dx.doi.org/10.18553/jmcp.2022.28.1.100 Text en Copyright © 2022, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Viewpoints Skelton, Jann B Dharbhamalla, Vyishali The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group |
title | The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group |
title_full | The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group |
title_fullStr | The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group |
title_full_unstemmed | The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group |
title_short | The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group |
title_sort | role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the amcp addiction advisory group |
topic | Viewpoints |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372947/ https://www.ncbi.nlm.nih.gov/pubmed/34949114 http://dx.doi.org/10.18553/jmcp.2022.28.1.100 |
work_keys_str_mv | AT skeltonjannb theroleofmanagedcarepharmacyincoprescribingnaloxoneforpatientswithspecificriskrecommendationsfromtheamcpaddictionadvisorygroup AT dharbhamallavyishali theroleofmanagedcarepharmacyincoprescribingnaloxoneforpatientswithspecificriskrecommendationsfromtheamcpaddictionadvisorygroup AT skeltonjannb roleofmanagedcarepharmacyincoprescribingnaloxoneforpatientswithspecificriskrecommendationsfromtheamcpaddictionadvisorygroup AT dharbhamallavyishali roleofmanagedcarepharmacyincoprescribingnaloxoneforpatientswithspecificriskrecommendationsfromtheamcpaddictionadvisorygroup |